While absolute rates of biopsy and post-biopsy complications have decreased following several benchmark prostate-specific antigen screening publications, the relative risk for each patient continues to increase, according to a new study.
While absolute rates of biopsy and post-biopsy complications have decreased following several benchmark prostate-specific antigen screening publications, the relative risk for each patient continues to increase, according to a new study.